Kymera Therapeutics to Participate in Upcoming June Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
Kymera Therapeutics (KYMR) PT Raised to $60 at Citi
June 2, 2025 2:09 PM EDTCiti analyst Geoff Meacham raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $60.00 (from $52.00) while maintaining a Buy rating.
The analyst comments "Today's positive phase 1 healthy volunteer data for KT-621 (STAT6 degrader) de-risks the asset in our view and underscores the... More
Citi Reiterates Buy Rating on Kymera Therapeutics (KYMR)
June 2, 2025 8:04 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $52.00 price target on Kymera Therapeutics (NASDAQ: KYMR).
The analyst comments "Earlier today, Kymera presented positive phase 1 results of its STAT-6 degrader (KT-621). The drug achieved exceptional STAT6 degradation, exceeding 90% mean degradation in blood... More
